This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rajpal, G. Articles by Arvan, P. Search for Related Content PubMed PubMed Citation Articles by Rajpal, G. Articles by Arvan, P.

Single-Chain Insulins as Receptor Agonists

Cell and Molecular Biology Program (G.R., P.A.) and the Division of Metabolism, Endocrinology, and Diabetes (M.L., Y.Z., P.A.), University of Michigan Medical Center, Ann Arbor Michigan 48109

Address all correspondence and requests for reprints to: Peter Arvan, M.D., Ph.D., Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, 5560 MSRB2, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0678. E-mail: parvan{at}umich.edu.

Single-chain insulins (SCIs) are single polypeptide chains in which the insulin B-chain links contiguously with the insulin A-chain via an uncleaved connecting peptide. Although direct linkage of insulin B- and A-chains produces SCIs with little insulin receptor binding, biologists have been interested in bioengineering linker peptides that form a flexible reverse turn, allowing SCIs to activate insulin receptors. In this report, we have investigated a series of cDNAs intended to explore the significance of linker length, cleavability, and the impact of certain site-dependent residues for the bioactivity of recombinant SCIs on insulin receptors. SCI concentration is readily measured by RIA with a (proinsulin plus insulin)-specific polyclonal antibody. Although dibasic flanking residues may result in potential endoproteolytic susceptibility, a linker with -Gln-Arg- flanking sequences resisted cleavage even in secretory granules, ensuring single-chain behavior. Effective SCIs exhibit favorable and specific binding with insulin receptors. SCIs with linkers bearing an Arg residue immediately preceding the A-chain were most bioactive, although efficient receptor interaction was inhibited as SCI linker length increased, approaching that observed for proinsulin. SCIs activate downstream metabolic signaling, stimulating glucose uptake into adipocytes and suppressing gluconeogenic enzyme biosynthesis in hepatocytes, with only limited cross-reactivity on IGF-I receptors. SCIs might theoretically have utility either in immunotherapy or gene therapy in insulin-deficient diabetes.